secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001193125-26-120770
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm SENTRY trial meets spleen endpoint, misses symptom; DLBCL withdrawal agreed
--------------------------------------------------------------------------------

- SENTRY trial: 50% SVR35 at wk24 vs 28% for ruxolitinib alone (p<0.0001); Abs-TSS comparable, not significant.
- Promising OS signal: HR 0.43 (95% CI 0.19–1.00, nominal p=0.0222); continued follow-up planned.
- FDA requested withdrawal of accelerated approval for XPOVIO in DLBCL; company agreed, ceases development.
- Private placement with RA Capital: ~$30M gross (1.03M shares at $6.785, pre-funded warrants); warrants at $10.
- ATM sales in March 2026 raised ~$9.6M net; capital raise trigger satisfied for credit agreement amendments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526120770/0001193125-26-120770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526120770/d125009d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-120770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer